• Contact Email webemail06@chelseatherapeutics.com
  • Phone Number (704) 341-1516

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions

and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.

Lists Featuring This Company

Companies That Exited in 2004
2,961 Number of Organizations • $82.3B Total Funding Amount • 1,830 Number of Investors
Closed United States Biotechnology Companies
2,257 Number of Organizations • $65.8B Total Funding Amount • 4,736 Number of Investors
North Carolina Companies that Exited
1,802 Number of Organizations • $46.9B Total Funding Amount • 1,314 Number of Investors
Companies that Went Public in 2004
1,318 Number of Organizations • $75.1B Total Funding Amount • 792 Number of Investors
Chelsea Therapeutics International was acquired by Lundbeck for $658M on May 8, 2014.

Frequently Asked Questions